Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy

Due to the lack of efficient therapeutic options and clinical trial limitations, the FDA-approved drugs can be a good choice to handle Coronavirus disease (COVID-19). Many reports have enough evidence for the use of FDA-approved drugs which have inhibitory potential against target proteins of Severe...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Biosci Rep
Autors principals: Shamsi, Anas, Mohammad, Taj, Anwar, Saleha, AlAjmi, Mohamed F., Hussain, Afzal, Rehman, Md. Tabish, Islam, Asimul, Hassan, Md. Imtaiyaz
Format: Artigo
Idioma:Inglês
Publicat: Portland Press Ltd. 2020
Matèries:
Bioinformatics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7268261/
https://ncbi.nlm.nih.gov/pubmed/32441299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1042/BSR20201256
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars